A TNFR2 antagonists could specifically inhibit CD4+Foxp3+ Tregs expansion in the tumor microenvironment, whereas it had little inhibitory effects on CD4+ Tregs in periphery or from healthy donors, and killed human ovarian tumor cells directly. This evidence concerns the gene TNFRSF1B and ovarian neoplasm.